Cargando…

Advances in the surgical treatment of esophageal cancer since 1965

In Japan, the treatment of esophageal cancer has undergone significant development since the Japanese Society for Esophageal Diseases was established in 1965 by Doctors Komei Nakayama, Shigetsugu Katsura, and Ichiro Akakura. When the Society was established, surgery was the first‐line treatment for...

Descripción completa

Detalles Bibliográficos
Autor principal: Matsubara, Hisahiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7240144/
https://www.ncbi.nlm.nih.gov/pubmed/32490339
http://dx.doi.org/10.1002/ags3.12332
_version_ 1783536821053947904
author Matsubara, Hisahiro
author_facet Matsubara, Hisahiro
author_sort Matsubara, Hisahiro
collection PubMed
description In Japan, the treatment of esophageal cancer has undergone significant development since the Japanese Society for Esophageal Diseases was established in 1965 by Doctors Komei Nakayama, Shigetsugu Katsura, and Ichiro Akakura. When the Society was established, surgery was the first‐line treatment for esophageal cancer. Since then, the Society has been led by three successive chairpersons—Doctors Katsura, Nakayama, and Satoh. Over this time, surgery‐related mortalities declined to 5%‐6% because of the rapid improvements in surgical technique. Beginning in 1980, the bilateral cervical lymph node dissection technique gained attention, and favorable long‐term outcomes were gradually reported. A nationwide questionnaire survey, conducted by the Society in 1990, showed that more favorable long‐term outcomes were achieved by following the three‐field lymph node dissection technique than by following the two‐field lymph node dissection technique. Since then, the three‐field lymph node dissection technique has been recognized and widely used as the standard surgical procedure for treating esophageal cancer. After clinical studies examined the utility of various pre‐ and postoperative adjunctive therapies in outcome improvements, preoperative chemotherapy was recognized as the standard treatment in the therapy guidelines. Additionally, less invasive surgical methods have been developed, including endoscopic and robot‐assisted surgeries, which are applied in general practice now. However, unresectable and recurrent esophageal cancers remain difficult to treat, and additional treatments should be developed.
format Online
Article
Text
id pubmed-7240144
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-72401442020-06-01 Advances in the surgical treatment of esophageal cancer since 1965 Matsubara, Hisahiro Ann Gastroenterol Surg Review Articles In Japan, the treatment of esophageal cancer has undergone significant development since the Japanese Society for Esophageal Diseases was established in 1965 by Doctors Komei Nakayama, Shigetsugu Katsura, and Ichiro Akakura. When the Society was established, surgery was the first‐line treatment for esophageal cancer. Since then, the Society has been led by three successive chairpersons—Doctors Katsura, Nakayama, and Satoh. Over this time, surgery‐related mortalities declined to 5%‐6% because of the rapid improvements in surgical technique. Beginning in 1980, the bilateral cervical lymph node dissection technique gained attention, and favorable long‐term outcomes were gradually reported. A nationwide questionnaire survey, conducted by the Society in 1990, showed that more favorable long‐term outcomes were achieved by following the three‐field lymph node dissection technique than by following the two‐field lymph node dissection technique. Since then, the three‐field lymph node dissection technique has been recognized and widely used as the standard surgical procedure for treating esophageal cancer. After clinical studies examined the utility of various pre‐ and postoperative adjunctive therapies in outcome improvements, preoperative chemotherapy was recognized as the standard treatment in the therapy guidelines. Additionally, less invasive surgical methods have been developed, including endoscopic and robot‐assisted surgeries, which are applied in general practice now. However, unresectable and recurrent esophageal cancers remain difficult to treat, and additional treatments should be developed. John Wiley and Sons Inc. 2020-04-14 /pmc/articles/PMC7240144/ /pubmed/32490339 http://dx.doi.org/10.1002/ags3.12332 Text en © 2020 The Authors. Annals of Gastroenterological Surgery published by John Wiley & Sons Australia, Ltd on behalf of The Japanese Society of Gastroenterological Surgery This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Articles
Matsubara, Hisahiro
Advances in the surgical treatment of esophageal cancer since 1965
title Advances in the surgical treatment of esophageal cancer since 1965
title_full Advances in the surgical treatment of esophageal cancer since 1965
title_fullStr Advances in the surgical treatment of esophageal cancer since 1965
title_full_unstemmed Advances in the surgical treatment of esophageal cancer since 1965
title_short Advances in the surgical treatment of esophageal cancer since 1965
title_sort advances in the surgical treatment of esophageal cancer since 1965
topic Review Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7240144/
https://www.ncbi.nlm.nih.gov/pubmed/32490339
http://dx.doi.org/10.1002/ags3.12332
work_keys_str_mv AT matsubarahisahiro advancesinthesurgicaltreatmentofesophagealcancersince1965